CSTL
Castle Biosciences, Inc.NASDAQHealthcare$24.84-0.84%ClosedMarket Cap: $738.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.55
P/S
2.15
EV/EBITDA
50.15
DCF Value
$-187.23
FCF Yield
3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.7%
Operating Margin
-12.4%
Net Margin
-7.0%
ROE
-5.3%
ROA
-5.0%
ROIC
-6.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $87.0M | 36.6% | $-3.8M | $-2.3M | $-0.08 | — |
| FY 2025 | $344.2M | 68.7% | $-42.8M | $-24.2M | $-0.83 | — |
| Q3 2025 | $83.0M | 77.5% | $-6.8M | $-501.0K | $-0.02 | — |
| Q2 2025 | $86.2M | 79.5% | $-4.3M | $4.5M | $0.15 | — |
| Q1 2025 | $88.0M | 81.4% | $-27.9M | $-25.8M | $-0.90 | — |
| Q4 2024 | $86.3M | 81.3% | $4.0M | $9.6M | $0.32 | — |
| FY 2024 | $332.1M | 81.9% | $8.7M | $18.2M | $0.62 | — |
| Q3 2024 | $85.8M | 81.8% | $5.1M | $2.3M | $0.08 | — |
| Q2 2024 | $87.0M | 83.3% | $5.0M | $8.9M | $0.31 | — |
| Q1 2024 | $73.0M | 81.0% | $-5.5M | $-2.5M | $-0.09 | — |
| Q4 2023 | $66.1M | 81.2% | $-5.7M | $-2.6M | $-0.10 | — |
| FY 2023 | $219.8M | 79.5% | $-68.0M | $-57.5M | $-2.14 | — |